Improved treatment of type 2 diabetes mellitus by improving the splenic functions and gastro intestinal tract using naturally occurring bioactive compounds

Phase 3

Completed

• Conditions: Splenic and gastro intestinal disorder in Type 2 Diabetes Mellitus; gastrointestinal disorder; Diabetes mellitus; Metabolic diseases; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12614000007639
• Lead Sponsor: guyen Van Toan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 94

Inclusion Criteria

All participated patients aged between 52-85 years old, diagnosed with type 2 diabetes mellitus were informed about the purposes, methods and intended uses of the research. They were informed about what participation will involve and the risks as well as potential benefits explained. Moreover. the participants were allowed to withdraw themselves from participation at any time and for any reason without disadvantage and all information as well as data obtained about participants were confidential

Exclusion Criteria

Out of age range of 52-85

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The effect of ANIVINA on lowering blood glucose levels after taking the ANIVINA for 183 days as assessed by the HbA1c test. HbA1c test was performed by using Direct Enzymatic HbA1c Method applying Chromatography based HPLC assay.[Assessed on a monthly basis throughout the duration of the treatment, and at 6 months after end of treatment<br><br>]

Secondary Outcome Measures

Name	Time	Method
The effect of ANIVINA on postprandial blood glucose levels<br><br>HbA1c test was performed by using Direct Enzymatic HbA1c Method[ Assessed at 6 months when the intervention treatment has been completed ]